Here's What Lifted bluebird bio Inc. Stock 40% Higher in August
Shares of bluebird bio Inc. (NASDAQ: BLUE), a clinical-stage biotech developing cell-based therapies, soared 40% in August, according to data from S&P Global Market Intelligence. A generous takeover offer for an industry peer and an FDA approval for another treatment boosted the market's confidence for bluebird's pipeline.
Bluebird bio's development pipeline is full of experimental therapies that involve modifying a patient's own cells before reintroducing them. Last month, Gilead Sciences (NASDAQ: GILD) shook up the industry with an $11.9 billion buyout offer for Kite Pharma (NASDAQ: KITE), another clinical-stage biotech developing cell-based therapies similar to those in bluebird bio's pipeline. Gilead is notorious for both success and prudence when it makes big purchases, which is why announcing a deal for Kite provided a big lift for related stocks.
Image source: Getty Images.
Source: Fool.com
Gilead Sciences Inc Stock
We see a rather positive sentiment for Gilead Sciences Inc with 11 Buy predictions and 1 Sell predictions.
With a target price of 85 € there is a slightly positive potential of 18.93% for Gilead Sciences Inc compared to the current price of 71.47 €.
